SABS: SAB Biotherapeutics, Inc Price to Sales
While global conflicts and sanctions may disrupt raw material supply chains, the implementation of autonomous bioreactors ensures sterility during antibody production for SAB Biotherapeutics (SABS). The current P/S valuation visualizes market demand for sales, where 1668.60 shows the current volume of this metric. Business stability currently relies on the test results of diabetes drugs to reduce dependence on a single serum procurement technology.
SAB Biotherapeutics, Inc (SABS) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Equity SAB Biotherapeutics|SABS - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SAB Biotherapeutics Inc|SABS - Company Aggregate Debts|Debt to Book Capitalization Ratio SAB Biotherapeutics, Inc|SABS - Company Long-Term Debts|Short-Term Debt Volume SAB Biotherapeutics|Immediate Liquidity sabbiotherapeutics.com
- net income and valuation ratios data:
SABS - Net Income|Future Net Profit SAB Biotherapeutics|SABS - P/E Multiple|Future Price to Earnings Multiple SAB Biotherapeutics Inc.|SABS - PEG Multiple|Company Value to EBITDA SAB Biotherapeutics, Inc|SABS - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year SAB Biotherapeutics|SABS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth sabbiotherapeutics.com|SABS - Earnings per share growth in current year|Net earnings per share change forecast for next year SAB Biotherapeutics
- issuer revenue and sales details:
General company analysis:sabbiotherapeutics.com SABS
The P/S multiple determines the market value of a business relative to its annual revenue, measuring investors' willingness to pay per unit of sales. For SAB Biotherapeutics (SABS), this metric reflects expectations regarding the commercialization of the DiversitAb platform and successes in diabetes therapy. By analyzing the price/sales multiple level, one can assess the extent of future revenue potential already priced in. This metric is critical for determining whether the asset is overbought.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Protagonist Corp PTGX|IMVT: P/S Multiple|kiniksa.com (KNSA) - P/S Multiple|GRFS (Grifols) - P/S Multiple|Price-to-Revenue Ratio ADPT|Market Cap to Revenue CLDX (Celldex)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Pharvaris NV PHVS|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Price to Sales Tourmaline (TRML)|Market Cap to Revenue PGEN|PHAR (pharming.com) - Market Cap to Sales Volume|P/S Multiple NKTR|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Immunome Bio (IMNM) - Price to Sales|GOSS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|Pieris Pharma (PVLA) - P/S Multiple|Price-to-Revenue Ratio Savara Corp|Rigel Corp - Price-to-Sales Ratio|P/S Multiple ANAB|ATXS - Price to Sales|enGene - Market Cap to Revenue|P/S Multiple RAPT Therapeutics Inc. RAPT|JBIO: Market Cap to Revenue|Aclaris Therapeutics, Inc - Market Cap to Sales Volume|KYTX: P/S Multiple|TLSA - Price-to-Revenue Coefficient|CABA (Cabaletta Bio) - P/S Multiple|Market Cap to Revenue Ventyx Biosciences Inc. (VTYX)|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Price-to-Revenue Coefficient Avalo Therapeutics Inc|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|Price-to-Revenue Coefficient agenusbio.com (AGEN)|Climb Bio - P/S Multiple|ZURA - P/S Multiple|ATYR: P/S Multiple|ADAG (Adagene Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio ImageneBio|Shattuck Therapeutics (STTK) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Equillium, Inc. (EQ)|CNTB: Price-to-Sales Ratio|P/S Multiple IMUX (Immunic)|Market Capitalization-to-Revenue Ratio ATRA|InflaRx GmbH - P/S Multiple|XFOR - P/S Multiple|adicetbio.com (ACET) - Price-to-Revenue Ratio|Celularity - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio INmune Bio Corp|Market Cap to Revenue Barinthus Biotherapeutics Corp (BRNS)|P/S Multiple KZR|P/S Multiple akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTTB|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Coefficient Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|Market Cap to Revenue HCWB (HCW Biologics Inc.)|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|REVB - Price-to-Revenue Coefficient|INDP (Indaptus Therapeutics) - P/S Multiple|P/S Multiple scinai.com|P/S Multiple CALI|Price-to-Revenue Ratio AFMD (affimed.com)|Allakos - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|ITOS: Price-to-Revenue Ratio|OCEA: P/S Multiple|TCBP - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Third Harmonic Bio, Inc
